Ras-MAP kinase signaling pathways and control of cell proliferation: Relevance to cancer therapy

Critical Reviews in Clinical Laboratory Sciences

Volumn 39, Issue 4-5, 2002, Pages 285-330

  Shapiro, Paul ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Cancer; Cell cycle checkpoints; Cell proliferation; Drug discovery; Phosphorylation; Signal transduction

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN;

APOPTOSIS; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG DESIGN; DRUG SCREENING; ENZYME ACTIVATION; ENZYME INHIBITION; MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL DIVISION; DRUG DESIGN; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; RAS PROTEINS;

EID: 0036400204     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408360290795538     Document Type: Review

References (353)

1. Kalckar HM Biological phosphorylations; development of concepts, Prentice-Hall, Englewood Cliffs, N.J., 1969.
2. Sutherland EW. Studies on the mechanism of hormone action. Science 1972; 177: 401-408.
3. Raju, TN. The Nobel chronicles. 1992: Edmond H Fischer (b 1920) and Edwin G Krebs (b 1918). Lancet 2000; 355: 2004.
4. Whalen AM, Galasinski SC, Shapiro PS, et al. Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase. Mol Cell Biol 1997; 17: 1947-1958.
5. Campbell SL, Khosravi-Far R, Rossman KL, et al. Increasing complexity of Ras signaling. Oncogene 1998; 17: 1395-1413.
6. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
7. Chang EH, Furth ME, Scolnick EM, et al. Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature 1982; 297: 479-483.
8. Parada LF, Tabin CJ, Shih C, et al. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982; 297: 474-478.
9. Grucza RA, Bradshaw JM, Futterer K, et al. SH2 domains: from structure to energetics, a dual approach to the study of structure-function relationships. Med Res Rev 1999; 19: 273-293.
10. Waksman G, Shoelson SE, Pant N, et al. Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms. Cell 1993; 72: 779-790.
11. Poy F, Yaffe MB, Sayos J, et al. Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition. Mol Cell 1999; 4: 555-561.
12. VanderKuur J, Allevato G, Billestrup N, et al. Growth hormone-promoted tyrosyl phosphorylation of SHC proteins and SHC association with Grb2. J Biol Chem 1995; 270: 7587-7593.
13. Hu Y, Bowtell DD. Sos1 rapidly associates with Grb2 and is hypophosphorylated when complexed with the EGF receptor after EGF stimulation. Oncogene 1996; 12: 1865-1872.
14. Lim WA, Richards FM, Fox RO. Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains. Nature 1994; 372: 375-379.
15. Fucini RV, Okada S, Pessin JE. Insulin-induced desensitization of extracellular signal-regulated kinase activation results from an inhibition of Raf activity independent of Ras activation and dissociation of the Grb2-SOS complex. J Biol Chem 1999; 274: 18651-18658.
16. Qian X, Vass WC, Papageorge AG, et al. N terminus of Sos1 Ras exchange factor: critical roles for the Db1 and pleckstrin homology domains. Mol Cell Biol 1998; 18: 771-778.
17. Della Rocca GJ, Maudsley S, Daaka Y, et al. Pleiotropic coupling of G protein-coupled receptors to the mitogen-activated protein kinase cascade. Role of focal adhesions and receptor tyrosine kinases. J Biol Chem 1999; 274: 13978-13984.
18. Guan JL. Focal adhesion kinase in integrin signaling. Matrix Biol 1997; 16: 195-200.
19. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995; 268: 233-239.
20. Luttrell LM, Daaka Y, Della Rocca GJ, et al. G protein-coupled receptors mediate two functionally distinct pathways of tyrosine phosphorylation in rat 1a fibroblasts. Shc phosphorylation and receptor endocytosis correlate with activation of Erk kinases. J Biol Chem 1997; 272: 31648-31656.
21. Daub H, Wallasch C, Lankenau A, et al. Signal characteristics of G protein-transactivated EGF receptor. EMBO J 1997; 16: 7032-7044.
22. Daub H, Weiss FU, Wallasch C, et al. Role of transactivation of the EGF receptor in signalling by G-protein- coupled receptors. Nature 1996; 379: 557-560.
23. Khosravi-Far R, Campbell S, Rossman KL, et al. Increasing complexity of Ras signal transduction: involvement of Rho family proteins. Adv Cancer Res 1998; 72: 57-107
24. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
25. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905-2927.
26. Hu Q, Klippel A, Muslin AJ, et al. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 1995; 268: 100-102
27. Chaudhary LR, Hruska KA. The cell survival signal Akt is differentially activated by PDGFBB, EGF, and FGF-2 in osteoblastic cells. J Cell Biochem 2001; 81: 304-311.
28. Weng LP, Smith WM, Brown JL, et al. PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet 2001; 10: 605-616.
29. Bryant SS, Mitchell AL, Collins F, et al. N-terminal sequences contained in the Src homology 2 and 3 domains of p120 GTPase-activating protein are required for full catalytic activity toward Ras. J Biol Chem 1996; 271: 5195-5199.
30. Sinensky M, Lutz RJ. The prenylation of proteins. Bioessays 1992; 14: 25-31.
31. Khosravi-Far R, Cox AD, Kato K, et al. Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ 1992; 3: 461-469.
32. Strickland CL, Windsor WT, Syto R, et al. Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. Biochemistry 1998; 37: 16601-16611.
33. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000; 96: 1655-1669.
34. Crul M, de Klerk GJ, Beijnen JH, et al. Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anticancer Drugs 2001; 12: 163-184.
35. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994; 77: 175-178.
36. Reuveni H, Geiger T, Geiger B, et al. Reversal of the Ras-induced transformed phenotype by HR12, a novel ras farnesylation inhibitor, is mediated by the Mek/Erk pathway. J Cell Biol 2000; 151: 1179-1192.
37. Rodenhuis S. ras and human tumors. Semin Cancer Biol 1992; 3: 241-247.
38. Ashar HR, James L, Gray K, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 2000; 275: 30451-30457.
39. Feldkamp MM, Lau N, Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 1999; 18: 7514-7526.
40. Pawson T, Olivier P, Rozakis-Adcock M, et al. Proteins with SH2 and SH3 domains couple receptor tyrosine kinases to intracellular signalling pathways. Philos Trans R Soc Lond B Biol Sci 1993; 340: 279-285.
41. Cody WL, Lin Z, Panek RL, et al. Progress in the development of inhibitors of SH2 domains. Curr Pharm Des 2000; 6: 59-98.
42. Violette SM, Guan W, Bartlett C, et al. Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption. Bone 2001; 28: 54-64.
43. Shakespeare WC. SH2 domain inhibition: a problem solved? Curr Opin Chem Biol 2001; 5: 409-415.
44. Vu CB. Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP70. Curr Med Chem 2000; 7: 1081-1100.
45. Li Y, He X, Schembri-King J, et al. Cloning and characterization of human Lnk, an adaptor protein with pleckstrin homology and Src homology 2 domains that can inhibit T cell activation. J Immunol 2000; 164: 5199-5206.
46. Yao ZJ, King CR, Cao T, et al. Potent inhibition of Grb2 SH2 domain binding by non-phosphate- containing ligands. J Med Chem 1999; 42: 25-35.
47. Gao Y, Luo J, Yao ZJ, et al. Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. J Med Chem 2000; 43: 911-920.
48. Ray LB, Sturgill TW. Rapid stimulation by insulin of a serine/threonine kinase in 3T3-L1 adipocytes that phosphorylates microtubule-associated protein 2 in vitro. Proc Natl Acad Sci USA 1987; 84: 1502-1506.
49. Ray LB, Sturgill TW. Insulin-stimulated microtubule-associated protein kinase is phosphorylated on tyrosine and threonine in vivo. Proc Natl Acad Sci USA 1988; 85: 3753-3757.
50. Boulton TG, Cobb MH. Identification of multiple extracellular signal-regulated kinases (ERKs) with antipeptide antibodies. Cell Regul 1991; 2: 357-371.
51. Lewis TS, Shapiro PS, Ahn NG. Signal tranduction through MAP Kinase Cascades. Advan Cancer Res 1998; 74: 49-139
52. Derijard B, Raingeaud J, Barrett T, et al. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms (published erratum appears in Science 1995 Jul 7;269[5220]:17). Science 1995; 267: 682-685.
53. Boulton TG, Nye SH, Robbins DJ, et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991; 65: 663-675.
54. Ahn NG, Seger R, Bratlien RL, et al. Multiple components in an epidermal growth factor-stimulated protein kinase cascade. In vitro activation of a myelin basic protein/microtubule-associated protein 2 kinase. J Biol Chem 1991; 266: 4220-4227.
55. Schaeffer HJ, Catling AD, Eblen ST, et al. MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade. Science 1998; 281: 1668-1671.
56. Wunderlich W, Fialka I, Teis D, et al. A novel 14-kilodalton protein interacts with the mitogen-activated protein kinase scaffold mp1 on a late endosomal/lysosomal compartment. J Cell Biol 2001; 152: 765-776.
57. Fukuda M, Gotoh Y, Nishida E. Interaction of MAP kinase with MAP kinase kinase: its possible role in the control of nucleocytoplasmic transport of MAP kinase. EMBO J 1997; 16: 1901-1908
58. Haystead TA, Dent P, Wu J, et al. Ordered phosphorylation of p42mapk by MAP kinase kinase. FEBS Lett 1992; 306: 17-22.
59. Gotoh Y, Matsuda S, Takenaka K, et al. Characterization of recombinant Xenopus MAP kinase kinases mutated at potential phosphorylation sites. Oncogene 1994; 9: 1891-1898.
60. Zheng CF, Guan KL. Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues. EMBO J 1994; 13: 1123-1131.
61. Rossomando AJ, Dent P, Sturgill TW, et al. Mitogen-activated protein kinase kinase 1 (MKK1) is negatively regulated by threonine phosphorylation. Mol Cell Biol 1994; 14: 1594-1602.
62. Catling AD, Schaeffer HJ, Reuter CW, et al. A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function. Mol Cell Biol 1995; 15: 5214-5225.
63. Brunet A, Pages G, Pouyssegur J. Growth factor-stimulated MAP kinase induces rapid retrophosphorylation and inhibition of MAP kinase kinase (MEK1). FEBS Lett 1994; 346: 299-303
64. Nantel A, Mohammad-Ali K, Sherk J, et al. Interaction of the Grb10 adapter protein with the Raf1 and MEK1 kinases. J Biol Chem 1998; 273: 10475-10484.
65. Dang A, Frost JA, Cobb MH. The MEK1 proline-rich insert is required for efficient activation of the mitogen-activated protein kinases ERK1 and ERK2 in mammalian cells. J Biol Chem 1998; 273: 19909-19913.
66. Hagemann C, Rapp UR. Isotype-specific functions of Raf kinases. Exp Cell Res 1999; 253: 34-46.
67. Morrison DK, Cutler RE. The complexity of Raf-1 regulation. Curr Opin Cell Biol 1997; 9: 174-179
68. Zhang XF, Settleman J, Kyriakis JM, et al. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 1993; 364: 308-313
69. Leevers SJ, Paterson HF, Marshall CJ. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 1994; 369: 411-414.
70. Stokoe D, Macdonald SG, Cadwallader K, et al. Activation of Raf as a result of recruitment to the plasma membrane. Science 1994; 264: 1463-1467.
71. Dent P, Jelinek T, Morrison DK, et al. Reversal of Raf-1 activation by purified and membrane-associated protein phosphatases (published erratum appears in Science 1995 Sep 22;269[5231]:1657). Science 1995; 268: 1902-1906
72. Jelinek T, Dent P, Sturgill TW, et al. Ras-induced activation of Raf-1 is dependent on tyrosine phosphorylation. Mol Cell Biol 1996; 16: 1027-1034.
73. Cleghon V, Morrison DK. Raf-1 interacts with Fyn and Src in a non-phosphotyrosine-dependent manner. J Biol Chem 1994; 269: 17749-17755.
74. Fabian JR, Daar IO, Morrison DK. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol 1993; 13: 7170-7179.
75. Marais R, Light Y, Paterson HF, et al. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J 1995; 14: 3136-3145.
76. Kolch W, Heidecker G, Kochs G, et al. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 1993; 364: 249-252.
77. Zhang Y, Yao B, Delikat S, et al. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 1997; 89: 63-72
78. Xing HR, Kolesnick R. Kinase suppressor of Ras signals through Thr269 of c-Raf-1. J Biol Chem 2001; 276: 9733-9741.
79. Morrison DK. KSR: a MAPK scaffold of the Ras pathway? J Cell Sci 2001; 114: 1609-1612.
80. Sun H, King AJ, Diaz HB, et al. Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak. Curr Biol 2000; 10: 281-284
81. Chiloeches A, Mason CS, Marais R. S338 phosphorylation of Raf-1 is independent of phosphatidylinositol 3-kinase and Pak3. Mol Cell Biol 2001; 21: 2423-2434.
82. Sevetson BR, Kong X, Lawrence JC, Jr. Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc Natl Acad Sci USA 1993; 90: 10305-10309.
83. Cook SJ and McCormick F. Inhibition by cAMP of Ras-dependent activation of Raf. Science 1993; 262: 1069-1072.
84. Wu J, Dent P, Jelinek T, et al. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science 1993; 262: 1065-1069.
85. Sidovar MF, Kozlowski P, Lee JW, et al. Phosphorylation of serine 43 is not required for inhibition of c-Raf kinase by the cAMP-dependent protein kinase. J Biol Chem 2000; 275: 28688-28694.
86. Qiu W, Zhuang S, von Lintig FC, et al. Cell type-specific regulation of B-Raf kinase by cAMP and 14-3-3 proteins. J Biol Chem 2000; 275: 31921-31929.
87. Rommel C, Clarke BA, Zimmermann S, et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999; 286: 1738-1741
88. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999; 286: 1741-1744
89. Muslin AJ, Tanner JW, Allen PM, et al. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 1996; 84: 889-897.
90. Fantl WJ, Muslin AJ, Kikuchi A, et al, Activation of Raf-1 by 14-3-3 proteins. Nature 1994; 371: 612-614.
91. Michaud NR, Fabian JR, Mathes KD, et al. 14-3-3 is not essential for Raf-1 function: identification of Raf-1 proteins that are biologically activated in a 14-3-3- and Ras- independent manner. Mol Cell Biol 1995; 15: 3390-3397
92. Jaumot M, Hancock JF. Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14- 3-3 interactions. Oncogene 2001; 20: 3949-3958.
93. MacNicol MC, Muslin AJ, MacNicol AM. Disruption of the 14-3-3 binding site within the B-Raf kinase domain uncouples catalytic activity from PC12 cell differentiation. J Biol Chem 2000; 275: 3803-3809.
94. Schulte TW, Blagosklonny MV, Ingui C, et al. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995; 270: 24585-24588.
95. Schulte TW, An WG, Neckers LM. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun 1997; 239: 655-659
96. Pritchard CA, Samuels ML, Bosch E, et al. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol Cell Biol 1995; 15: 6430-6442.
97. McCubrey JA, Steelman LS, Hoyle PE, et al. Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 1998; 12: 1903-1929.
98. Busca R, Abbe P, Mantoux F, et al. Ras mediates the cAMP-dependent activation of extracellular signal- regulated kinases (ERKs) in melanocytes. EMBO J 2000; 19: 2900-2910.
99. Singh B and Arlinghaus RB. The mos proto-oncogene product: its role in oocyte maturation, metaphase arrest, and neoplastic transformation. Mol Carcinog 1992; 6: 182-189.
100. Posada J, Yew N, Ahn NG, et al. Mos stimulates MAP kinase in Xenopus oocytes and activates a MAP kinase kinase in vitro. Mol Cell Biol 1993; 13: 2546-2553.
101. Fisher DL, Mandart E, Doree M. Hsp90 is required for c-Mos activation and biphasic MAP kinase activation in Xenopus oocytes. EMBO J 2000; 19: 1516-1524.
102. Kosako H, Gotoh Y, Nishida E. Requirement for the MAP kinase kinase/MAP kinase cascade in Xenopus oocyte maturation. EMBO J 1994; 13: 2131-2138.
103. Kosako H, Gotoh Y, Nishida E. Mitogen-activated protein kinase kinase is required for the mos-induced metaphase arrest. J Biol Chem 1994; 269: 28354-28358.
104. Sagata N, Oskarsson M, Copeland T, et al. Function of c-mos proto-oncogene product in meiotic maturation in Xenopus oocytes. Nature 1988; 335: 519-525.
105. Gotoh Y, Masuyama N, Dell K, et al. Initiation of Xenopus oocyte maturation by activation of the mitogen-activated protein kinase cascade. J Biol Chem 1995; 270: 25898-25904.
106. Ferrell JE, Jr. Xenopus oocyte maturation: new lessons from a good egg. Bioessays 1999; 21: 833-842.
107. Minshull J, Sun H, Tonks NK, et al. A MAP kinase-dependent spindle assembly checkpoint in Xenopus egg extracts. Cell 1994; 79: 475-486.
108. Lenormand P, Sardet C, Pages G, et al. Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts. J. Cell Biol. 1993; 122: 1079-1088.
109. Ward Y, Gupta S, Jensen P, et al. Control of MAP kinase activation by the mitogen-induced threonine/tyrosine phosphatase PAC1. Nature 1994; 367: 651-654.
110. Lenormand P, Sardet C, Pages G, et al. Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts. J Cell Biol 1993; 122: 1079-1088.
111. Khokhlatchev AV, Canagarajah B, Wilsbacher J, et al. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell 1998; 93: 605-615.
112. Rubinfeld H, Hanoch T, Seger R. Identification of a cytoplasmic-retention sequence in ERK2. J Biol Chem 1999; 274: 30349-30352.
113. Pulido R, Zuniga A, Ullrich A. PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal-regulated kinases ERK1 and ERK2 by association through a kinase interaction motif. EMBO J 1998; 17: 7337-7350.
114. Zuniga A, Torres J, Ubeda J, et al. Interaction of mitogen-activated protein kinases with the kinase interaction motif of the tyrosine phosphatase PTP-SL provides substrate specificity and retains ERK2 in the cytoplasm. J Biol Chem 1999; 274: 21900-21907.
115. Blanco-Aparicio C, Torres J, Pulido R. A novel regulatory mechanism of MAP kinases activation and nuclear translocation mediated by PKA and the PTP-SL tyrosine phosphatase. J Cell Biol 1999; 147: 1129-1136.
116. Jaaro H, Rubinfeld H, Hanoch T, et al. Nuclear translocation of mitogen-activated protein kinase kinase (MEK1) in response to mitogenic stimulation. Proc Natl Acad Sci USA 1997; 94: 3742-3747
117. Tolwinski NS, Shapiro PS, Goueli S, et al. Nuclear localization of mitogen-activated protein kinase kinase 1 (MKK1) is promoted by serum stimulation and G2-M progression. Requirement for phosphorylation at the activation lip and signaling downstream of MKK. J Biol Chem 1999; 274: 6168-6174.
118. Boulton TG, Nye SH, Robbins DJ, et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991; 65: 663-675.
119. Cheng M, Boulton TG, Cobb MH. ERK3 is a constitutively nuclear protein kinase. J Biol Chem 1996; 271: 8951-8958.
120. Turgeon B, Saba-El-Leil MK, Meloche S. Cloning and characterization of mouse extracellular-signal-regulated protein kinase 3 as a unique gene product of 100 kDa. Biochem J 2000; 346 Pt 1 169-175.
121. Peng X, Angelastro JM, Greene LA, Tyrosine phosphorylation of extracellular signal-regulated protein kinase 4 in response to growth factors. J Neurochem 1996; 66: 1191-1197.
122. Zhou G, Bao ZQ, Dixon JE. Components of a new human protein kinase signal transduction pathway. J Biol Chem 1995; 270: 12665-12669.
123. Lechner C, Zahalka MA, Giot JF, et al. ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. Proc Natl Acad Sci USA 1996; 93: 4355-4359.
124. Wang X, McGowan CH, Zhao M, et al. Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest. Mol Cell Biol 2000; 20: 4543-4552.
125. Abe MK, Kuo WL, Hershenson MB, et al. Extracellular signal-regulated kinase 7 (ERK7), a novel ERK with a C-terminal domain that regulates its activity, its cellular localization, cell growth. Mol Cell Biol 1999; 19: 1301-1312.
126. Zimmermann J, Lamerant N, Grossenbacher R, et al. Proteasome- and p38-dependent regulation of ERK3 expression. J Biol Chem 2001; 276: 10759-10766.
127. English JM, Pearson G, Hockenberry T, et al. Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control. J Biol Chem 1999; 274: 31588-31592.
128. Kato Y, Tapping RI, Huang S, et al. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 1998; 395: 713-716.
129. English JM, Pearson G, Baer R, et al. Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases. J Biol Chem 1998; 273: 3854-3860.
130. Pearson G, English JM, White MA, et al. ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation. J Biol Chem 2001; 276: 7927-7931.
131. Marinissen MJ, Chiariello M, Gutkind JS. Regulation of gene expression by the small GTPase Rho through the ERK6 (p38 gamma) MAP kinase pathway. Genes Dev 2001; 15: 535-553.
132. Abe MK, Kahle KT, Saelzler MP, et al. ERK7 is an autoactivated member of the MAPK family. J Biol Chem 2001; 276: 21272-21279.
133. Yung Y, Yao Z, Hanoch T, et al. ERK1b, a 46-kDa ERK isoform that is differentially regulated by MEK. J Biol Chem 2000; 275: 15799-15808.
134. Tibbles LA, Woodgett JR. The stress-activated protein kinase pathways. Cell Mol Life Sci 1999; 55: 1230-1254.
135. Kallunki T, Su B, Tsigelny I, et al. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev 1994; 8: 2996-3007.
136. Gupta S, Barrett T, Whitmarsh AJ, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996; 15: 2760-2770.
137. Paul A, Wilson S, Belham CM, et al. Stress-activated protein kinases: activation, regulation and function. Cell Signal 1997; 9: 403-410.
138. Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem 1998; 273: 1741-1748.
139. Schlesinger TK, Fanger GR, Yujiri T, et al. The TAO of MEKK. Front Biosci 1998; 3: D1181-1186.
140. Lange-Carter CA, Pleiman CM, Gardner AM, et al. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science 1993; 260: 315-319.
141. Minden A, Lin A, McMahon M, et al. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 1994; 266: 1719-1723.
142. Yujiri T, Sather S, Fanger GR, et al. Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption. Science 1998; 282: 1911-1914.
143. Karandikar M, Xu S, Cobb MH. MEKK1 binds raf-1 and the ERK2 cascade components. J Biol Chem 2000; 275: 40120-40127.
144. Matsumoto T, Yokote K, Tamura K, et al. Platelet-derived growth factor activates p38 mitogen-activated protein kinase through a Ras-dependent pathway that is important for actin reorganization and cell migration. J Biol Chem 1999; 274: 13954-13960.
145. Russell M, Lange-Carter CA, Johnson GL. Direct interaction between Ras and the kinase domain of mitogen-activated protein kinase kinase kinase (MEKK1). J Biol Chem 1995; 270: 11757-11760.
146. Widmann C, Gerwins P, Johnson NL, et al. MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis. Mol Cell Biol 1998; 18: 2416-2429.
147. Gibson S, Widmann C, Johnson GL. Differential involvement of MEK kinase 1 (MEKK1) in the induction of apoptosis in response to microtubule-targeted drugs versus DNA damaging agents. J Biol Chem 1999; 274: 10916-10922.
148. Ozaki I, Tani E, Ikemoto H, et al. Activation of stress-activated protein kinase/c-Jun NH2-terminal kinase and p38 kinase in calphostin C-induced apoptosis requires caspase-3- like proteases but is dispensable for cell death. J Biol Chem 1999; 274: 5310-5317.
149. Blagosklonny MV, Chuman Y, Bergan RC, et al. Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia 1999; 13: 1028-1036.
150. Holzman LB, Merritt SE, Fan G. Identification, molecular cloning, and characterization of dual leucine zipper bearing kinase. A novel serine/threonine protein kinase that defines a second subfamily of mixed lineage kinases. J Biol Chem 1994; 269: 30808-30817.
151. Ing YL, Leung IW, Heng HH, et al. MLK-3: identification of a widely-expressed protein kinase bearing an SH3 domain and a leucine zipper-basic region domain. Oncogene 1994; 9: 1745-1750.
152. Hirai S, Katoh M, Terada M, et al. MST/MLK2, a member of the mixed lineage kinase family, directly phosphorylates and activates SEK1, an activator of c-Jun N-terminal kinase/stress-activated protein kinase. J Biol Chem 1997; 272: 15167-15173.
153. Tibbles LA, Ing YL, Kiefer F, et al. MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and MKK3/6. Embo J 1996; 15: 7026-7035.
154. Merritt SE, Mata M, Nihalani D, et al. The mixed lineage kinase DLK utilizes MKK7 and not MKK4 as substrate. J Biol Chem 1999; 274: 10195-10202.
155. Hartkamp J, Troppmair J, Rapp UR. The JNK/SAPK activator mixed lineage kinase 3 (MLK3) transforms NIH 3T3 cells in a MEK-dependent fashion. Cancer Res 1999; 59: 2195-2202.
156. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 1995; 269: 1270-1272.
157. Bagrodia S, Derijard B, Davis RJ, et al. Cdc42 and PAK-mediated signaling leads to Jun kinase and p38 mitogen-activated protein kinase activation. J Biol Chem 1995; 270: 27995-27998.
158. Brown JL, Stowers L, Baer M, et al. Human Ste20 homologue hPAK1 links GTPases to the JNK MAP kinase pathway. Curr Biol 1996; 6: 598-605.
159. Frost JA, Steen H, Shapiro P, et al. Cross-cascade activation of ERKs and ternary complex factors by Rho family proteins. EMBO J 1997; 16: 6426-6438.
160. Alessi DR, Cuenda A, Cohen P, et al. PD 098059 is a specific inhibitor of the activation of mitogen- activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995; 270: 27489-27494.
161. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998; 273: 18623-18632.
162. Davies SP, Reddy H, Caivano M, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
163. Ahn NG, Nahreini TS, Tolwinski NS, et al. Pharmacologic inhibitors of MKK1 and MKK2. Methods Enzymol 2001; 332: 417-431.
164. Williams DH, Wilkinson SE, Purton T, et al. Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity. Biochemistry 1998; 37: 9579-9585.
165. Suzuki K, Kodama S, Watanabe M. Extremely low-dose ionizing radiation causes activation of mitogen-activated protein kinase pathway and enhances proliferation of normal human diploid cells. Cancer Res 2001; 61: 5396-5401.
166. Makin G, Dive C. Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy? Breast Cancer Res 2001; 3: 150-153.
167. Hayakawa J, Ohmichi M, Kurachi H, et al. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 1999; 274: 31648-31654.
168. Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 2000; 275: 39435-39443.
169. Kasid U, Suy S, Dent P, et al. Activation of Raf by ionizing radiation. Nature 1996; 382: 813-816.
170. Dent P, Reardon DB, Park JS, et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999; 10: 2493-2506.
171. Hagan M, Wang L, Hanley JR, et al. Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat Res 2000; 153: 371-383.
172. Bonner JA, Vroman BT, Christianson TJ, et al. Ionizing radiation-induced MEK and Erk activation does not enhance survival of irradiated human squamous carcinoma cells. Int J Radiat Oncol Biol Phys 1998; 42: 921-925.
173. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5: 810-816
174. Lackey K, Cory M, Davis R, et al. The discovery of potent cRaf1 kinase inhibitors. Bioorg Med Chem Lett 2000; 10: 223-226.
175. Hostein I, Robertson D, DiStefano F, et al. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001; 61: 4003-4009.
176. O'Dwyer PJ, Stevenson JP, Gallagher M, et al. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res 1999; 5: 3977-3982.
177. Stevenson JP, Yao KS, Gallagher M, et al. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol 1999; 17: 2227-2236.
178. Engelman JA, Lisanti MP, Scherer PE. Specific inhibitors of p38 mitogen-activated protein kinase block 3T3- L1 adipogenesis. J Biol Chem 1998; 273: 32111-32120.
179. Murray BW, Bennett BL, Sasaki DT. Analysis of pharmacologic inhibitors of Jun N-terminal kinases. Methods Enzymol 2001; 332: 432-452.
180. Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today 1999; 5: 439-447.
181. Hall-Jackson CA, Goedert M, Hedge P, et al. Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene 1999; 18: 2047-2054.
182. Lali FV, Hunt AE, Turner SJ, et al. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide- dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem 2000; 275: 7395-7402.
183. Bozyczko-Coyne D, O'Kane TM, Wu ZL, et al. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis. J Neurochem 2001; 77: 849-863.
184. Maroney AC, Finn JP, Connors TJ, et al. Cep-1347 (kt7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem 2001; 276: 25302-25308.
185. Villafania A, Anwar K, Amar S, et al. Glutathione-S-Transferase as a selective inhibitor of oncogenic ras-p21-induced mitogenic signaling through blockade of activation of jun by jun-N-terminal kinase. Ann Clin Lab Sci 2000; 30: 57-64.
186. Mody N, Leitch J, Armstrong C, et al. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett 2001; 502: 21-24.
187. Fukazawa H, Uehara Y. U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways. Cancer Res 2000; 60: 2104-2107.
188. Zhang Y, Dong Z, Nomura M, et al. Signal transduction pathways
189. Xia Z, Dickens M, Raingeaud J, et al. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326-1331.
190. Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 2000; 14: 6-16.
191. Alessi DR, Smythe C, Keyse SM. The human CL100 gene encodes a Tyr/Thr-protein phosphatase which potently and specifically inactivates MAP kinase and suppresses its activation by oncogenic ras in Xenopus oocyte extracts. Oncogene 1993; 8: 2015-2020.
192. Muda M, Boschert U, Smith A, et al. Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4. J Biol Chem 1997; 272: 5141-5151.
193. Tanoue T, Yamamoto T, Maeda R, et al. A Novel MAPK Phosphatase MKP-7 acts preferentially on JNK/SAPK and p38alpha and beta MAPKs. J Biol Chem 2001; 276: 26629-26639.
194. Muda M, Theodosiou A, Rodrigues N, et al. The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases. J Biol Chem 1996; 271: 27205-27208.
195. Theodosiou AM, Rodrigues NR, Nesbit MA, et al. A member of the MAP kinase phosphatase gene family in mouse containing a complex trinucleotide repeat in the coding region. Hum Mol Genet 1996; 5: 675-684.
196. Rohan PJ, Davis P, Moskaluk CA, et al. PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase. Science 1993; 259: 1763-1766.
197. Chu Y, Solski PA, Khosravi-Far R, et al. The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP- 2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J Biol Chem 1996; 271: 6497-6501.
198. Camps M, Nichols A, Gillieron C, et al. Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Science 1998; 280: 1262-1265.
199. Sun H, Charles CH, Lau LF, et al. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 1993; 75: 487-493.
200. Camps M, Chabert C, Muda M, et al. Induction of the mitogen-activated protein kinase phosphatase MKP3 by nerve growth factor in differentiating PC12. FEBS Lett 1998; 425: 271-276.
201. Brondello JM, Pouyssegur J, McKenzie FR. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 1999; 286: 2514-2517
202. Mumby MC, Walter G. Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth. Physiol Rev 1993; 73: 673-699.
203. Alessi DR, Gomez N, Moorhead G, et al. Inactivation of p42 MAP kinase by protein phosphatase 2A and a protein tyrosine phosphatase, but not CL100, in various cell lines. Curr Biol 1995; 5: 283-295.
204. Sontag E, Fedorov S, Kamibayashi C, et al. The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell 1993; 75: 887-897.
205. Alessi DR, Gomez N, Moorhead G, et al. Inactivation of p42 MAP kinase by protein phosphatase 2A and a protein tyrosine phosphatase, but not CL100, in various cell lines. Curr Biol 1995; 5: 283-295.
206. Millward TA, Zolnierowicz S, Hemmings BA. Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 1999; 24: 186-191.
207. Crews CM, Mohan R. Small-molecule inhibitors of the cell cycle. Curr Opin Chem Biol 2000; 4: 47-53.
208. Berndt N. Protein dephosphorylation and the intracellular control of the cell number. Front Biosci 1999; 4: D22-42.
209. Bastians H, Topper LM, Gorbsky GL, et al. Cell cycle-regulated proteolysis of mitotic target proteins. Mol Biol Cell 1999; 10: 3927-3941.
210. Morgan DO. Principles of CDK regulation. Nature 1995; 374: 131-134.
211. Pardee AB. G1 events and regulation of cell proliferation. Science 1989; 246: 603-608.
212. Kaelin WG, Jr. Functions of the retinoblastoma protein. Bioessays 1999; 21: 950-958.
213. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
214. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995; 11: 211-219.
215. Nilsson I, Hoffmann I. Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res 2000; 4: 107-114.
216. Sudakin V, Ganoth D, Dahan A, et al. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol Biol Cell 1995; 6: 185-197.
217. Lahav-Baratz S, Sudakin V, Ruderman JV, et al. Reversible phosphorylation controls the activity of cyclosome- associated cyclin-ubiquitin ligase. Proc Natl Acad Sci USA 1995; 92: 9303-9307.
218. Hartwell LH and Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989; 246: 629-634.
219. Elledge, SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996; 274: 1664-1672.
220. Hainaut P. The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival. Curr Opin Oncol 1995; 7: 76-82.
221. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433-439.
222. Matsuoka S, Rotman G, Ogawa A, et al. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 2000; 97: 10389-10394.
223. Brondello JM, Boddy MN, Furnari B, et al. Basis for the checkpoint signal specificity that regulates Chk1 and Cds1 protein kinases. Mol Cell Biol 1999; 19: 4262-4269.
224. Rieder CL, Salmon ED. The vertebrate cell kinetochore and its roles during mitosis. Trends Cell Biol 1998; 8: 310-318.
225. Nicklas RB. How cells get the right chromosomes. Science 1997; 275: 632-637.
226. Saavedra HI, Fukasawa K, Conn CW, et al. MAPK mediates RAS-induced chromosome instability. J Biol Chem 1999; 274: 38083-38090.
227. Gille H, Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem 1999; 274: 22033-22040.
228. Hipskind RA, Buscher D, Nordheim A, et al. Ras/MAP kinase-dependent and -independent signaling pathways target distinct ternary complex factors. Genes Dev 1994; 8: 1803-1816.
229. Lavoie JN, Rivard N, L'Allemain G, et al. A temporal and biochemical link between growth factor-activated MAP kinases, cyclin D1 induction and cell cycle entry. Prog Cell Cycle Res 1996; 2: 49-58.
230. Lavoie JN, L'Allemain G, Brunet A, et al. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996; 271: 20608-20616.
231. Raught B and Gingras AC. eIF4E activity is regulated at multiple levels. Int J Biochem Cell Biol 1999; 31: 43-57.
232. Dudley DT, Pang L, Decker SJ, et al. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995; 92: 7686-7689.
233. Pages G, Lenormand P, L'Allemain G, et al. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA 1993; 90: 8319-8323.
234. Frost JA, Geppert TD, Cobb MH, et al. A requirement for extracellular signal-regulated kinase (ERK) function in the activation of AP-1 by Ha-Ras, phorbol 12-myristate 13-acetate, and serum. Proc Natl Acad Sci USA 1994; 91: 3844-3848.
235. Brunet A, Pages G, Pouyssegur J. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 1994; 9: 3379-3387.
236. Seger R, Seger D, Reszka AA, et al. Overexpression of mitogen-activated protein kinase kinase (MAPKK) and its mutants in NIH 3T3 cells. Evidence that MAPKK involvement in cellular proliferation is regulated by phosphorylation of serine residues in its kinase subdomains VII and VIII. J Biol Chem 1994; 269: 25699-25709.
237. Balmanno K, Cook SJ. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 1999; 18: 3085-3097.
238. Lee RJ, Albanese C, Stenger RJ, et al. pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. J Biol Chem 1999; 274: 7341-7350.
239. Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J 1999; 18: 188-197.
240. Weber JD, Raben DM, Phillips PJ, et al. Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem J 1997; 326: 61-68.
241. Turchi L, Loubat, A Rochet N, et al. Evidence for a direct correlation between c-Jun NH2 terminal kinase 1 activation, cyclin D2 expression, and G(1)/S phase transition in the murine hybridoma 7TD1 cells. Exp Cell Res 2000; 261: 220-228.
242. Patel R, Bartosch B, Blank JL. p21WAF1 is dynamically associated with JNK in human T-lymphocytes during cell cycle progression. J Cell Sci 1998; 111: 2247-2255.
243. Hulleman E, Bijvelt JJ, Verkleij AJ, et al. Nuclear translocation of mitogen-activated protein kinase p42MAPK during the ongoing cell cycle, J Cell Physiol 1999; 180: 325-333.
244. Gille H, Kortenjann M, Thomae O, et al. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J 1995; 14: 951-962.
245. Kortenjann M, Thomae O, Shaw PE. Inhibition of v-raf-dependent c-fos expression and transformation by a kinase-defective mutant of the mitogen-activated protein kinase Erk2. Mol Cell Biol 1994; 14: 4815-4824.
246. Hodge C, Liao J, Stofega M, et al. Growth hormone stimulates phosphorylation and activation of elk-1 and expression of c-los, egr-1, and junB through activation of extracellular signal-regulated kinases 1 and 2. J Biol Chem 1998; 273: 31327-31336.
247. Yan YX, Nakagawa H, Lee MH, et al. Transforming growth factor-alpha enhances cyclin D1 transcription through the binding of early growth response protein to a cis-regulatory element in the cyclin D1 promoter. J Biol Chem 1997; 272: 33181-33190.
248. Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 1999; 19: 4672-4683.
249. Kortylewski M, Heinrich PC, Kauffmann ME, et al. Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells. Biochem J 2001; 357: 297-303.
250. Gartel AL, Ye X, Goufman E, et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA 2001; 98: 4510-4515.
251. Claassen GF, Hann SR. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. Proc Natl Acad Sci USA 2000; 97: 9498-9503.
252. Le Gallic L, Sgouras D, Beal G, Jr., et al. Transcriptional repressor ERF is a Ras/mitogen-activated protein kinase target that regulates cellular proliferation. Mol Cell Biol 1999; 19: 4121-4133.
253. Waskiewicz AJ, Flynn A, Proud CG, et al. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 1997; 16: 1909-1920.
254. Knauf U, Tschopp C, Gram H. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol 2001; 21: 5500-5511.
255. Wang X, Flynn A, Waskiewicz AJ, et al. The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways. J Biol Chem 1998; 273: 9373-9377
256. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80: 179-185.
257. Lin AW, Barradas M, Stone JC, et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998; 12: 3008-3019.
258. Auer KL, Park JS, Seth P, et al. Prolonged activation of the mitogen-activated protein kinase pathway promotes DNA synthesis in primary hepatocytes from p21Cip-1/WAF1-null mice, but not in hepatocytes from p16INK4a-null mice. Biochem J 1998; 336: 551-560.
259. Beier F, Taylor AC, LuValle P. The Raf-1/MEK/ERK pathway regulates the expression of the p21(Cip1/Waf1) gene in chondrocytes. J Biol Chem 1999; 274: 30273-30279.
260. Das D, Pintucci G, Stem A. MAPK-dependent expression of p21(WAF) and p27(kip1) in PMA-induced differentiation of HL60 cells. FEBS Lett 2000; 472: 50-52.
261. Tombes RM, Auer KL, Mikkelsen R, et al. The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic. Biochem J 1998; 330: 1451-1460.
262. Milne DM, Campbell DG, Caudwell FB, et al. Phosphorylation of the tumor suppressor protein p53 by mitogen- activated protein kinases. J Biol Chem 1994; 269: 9253-9260.
263. Milne DM, Campbell LE, Campbell DG, et al. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J Biol Chem 1995; 270: 5511-5518.
264. She QB, Chen N, Dong Z. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J Biol Chem 2000; 275: 20444-20449.
265. Bulavin DV, Saito S, Hollander MC, et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999; 18: 6845-6854.
266. Buschmann T, Adler V, Matusevich E, et al. p53 phosphorylation and association with murine double minute 2, c-Jun NH2-terminal kinase, p14ARF, and p300/CBP during the cell cycle and after exposure to ultraviolet irradiation. Cancer Res 2000; 60: 896-900.
267. Buschmann T, Potapova O, Bar-Shira A, et al. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol 2001; 21: 2743-2754.
268. Minden A, Lin A, Claret FX, et al. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 1995; 81: 1147-1157.
269. Coso OA, Chiariello M, Yu JC, et al. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK signaling pathway. Cell 1995; 81: 1137-1146.
270. Zhang S, Han J, Sells MA, et al. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J Biol Chem 1995; 270: 23934-23936.
271. Nagata K, Driessens M, Lamarche N, et al. Activation of G1 progression, JNK mitogen-activated protein kinase, and actin filament assembly by the exchange factor FGD1. J Biol Chem 1998; 273: 15453-15457.
272. Lamarche N, Tapon N, Stowers L, et al. Rac and Cdc42 induce actin polymerization and G1 cell cycle progression independently of p65PAK and the JNK/SAPK MAP kinase cascade. Cell 1996; 87: 519-529.
273. Molnar A, Theodoras AM, Zon LI, et al. Cdc42Hs, but not Rac1, inhibits serum-stimulated cell cycle progression at G1/S through a mechanism requiting p38/RK. J Biol Chem 1997; 272: 13229-13235.
274. Zhao JH, Reiske H, Guan JL. Regulation of the cell cycle by focal adhesion kinase. J Cell Biol 1998; 143: 1997-2008.
275. Oktay M, Wary KK, Dans M, et al. Integrin-mediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle. J Cell Biol 1999; 145: 1461-1469.
276. Zhao JH, Reiske H, Guan JL. Regulation of the cell cycle by focal adhesion kinase. J Cell Biol 1998; 143: 1997-2008.
277. Tamemoto H, Kadowaki T, Tobe K, et al. Biphasic activation of two mitogen-activated protein kinases during the cell cycle in mammalian cells. J Biol Chem 1992; 267: 20293-20297.
278. Heider H, Hug C, Lucocq JM. A 40-kDa myelin basic protein kinase, distinct from erk1 and erk2, is activated in mitotic HeLa cells. Eur J Biochem 1994; 219: 513-520.
279. Edelmann HM, Kuhne C, Petritsch C, et al. Cell cycle regulation of p70 S6 kinase and p42/p44 mitogen-activated protein kinases in Swiss mouse 3T3 fibroblasts. J Biol Chem 1996; 271: 963-971.
280. Chackalaparampil I, Shalloway D. Altered phosphorylation and activation of pp60c-src during fibroblast mitosis. Cell 1988; 52: 801-810.
281. Roche S, Fumagalli S, Courtneidge SA. Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division. Science 1995; 269: 1567-1569.
282. Laird AD, Taylor SJ, Oberst M, et al. Raf-1 is activated during mitosis. J Biol Chem 1995; 270: 26742-26745.
283. Laird AD, Morrison DK, Shalloway D. Characterization of Raf-1 activation in mitosis. J Biol Chem 1999; 274: 4430-4439.
284. Ziogas A, Lorenz IC, Moelling K, et al. Mitotic Raf-1 is stimulated independently of Ras and is active in the cytoplasm. J Biol Chem 1998; 273: 24108-24114.
285. Ravi RK, Weber E, McMahon M, et al. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest 1998; 101: 153-159.
286. Zhu J, Woods D, McMahon M, et al. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998; 12: 2997-3007.
287. Wright JH, Munar E, Jameson DR, et al. Mitogen-activated protein kinase kinase activity is required for the G(2)/M transition of the cell cycle in mammalian fibroblasts. Proc Natl Acad Sci USA 1999; 96: 11335-11340.
288. Hayne C, Tzivion G, Luo Z. Raf-1/MEK/MAPK pathway is necessary for the G2/M transition induced by nocodazole. J Biol Chem 2000; 275: 31876-31882.
289. Abbott DW, Holt JT. Mitogen-activated protein kinase kinase 2 activation is essential for progression through the G2/M checkpoint arrest in cells exposed to ionizing radiation. J Biol Chem 1999; 274: 2732-2742.
290. Zecevic M, Catling AD, Eblen ST, et al. Active MAP kinase in mitosis: localization at kinetochores and association with the motor protein CENP-E. J Cell Biol 1998; 142: 1547-1558.
291. Shapiro PS, Vaisberg E, Hunt A J, et al. Activation of the MKK/ERK pathway during somatic cell mitosis: direct interactions of active ERK with kinetochores and regulation of the mitotic 3F3/2 phosphoantigen. J Cell Biol 1998; 142: 1533-1545.
292. Cyert MS, Scherson T, Kirschner MW. Monoclonal antibodies specific for thiophosphorylated proteins recognize Xenopus MPF. Dev Biol 1988; 129: 209-216.
293. Campbell MS, Gorbsky GJ. Microinjection of mitotic cells with the 3F3/2 anti-phosphoepitope antibody delays the onset of anaphase. J Cell Biol 1995; 129: 1195-1204.
294. Daum JR, Gorbsky GJ. Casein kinase II catalyzes a mitotic phosphorylation on threonine 1342 of human DNA topoisomerase IIalpha, which is recognized by the 3F3/2 phosphoepitope antibody. J Biol Chem 1998; 273: 30622-30629.
295. Daum JR, Tugendreich S, Topper LM, et al. The 3F3/2 anti-phosphoepitope antibody binds the mitotically phosphorylated anaphase-promoting complex/cyclosome. Curr Biol 2000; 10: R850-852.
296. Shima DT, Haldar K, Pepperkok R, et al. Partitioning of the Golgi apparatus during mitosis in living HeLa cells. J Cell Biol 1997; 137: 1211-1228.
297. Acharya U, Mallabiabarrena A, Acharya JK, et al. Signaling via mitogen-activated protein kinase kinase (MEK1) is required for Golgi fragmentation during mitosis. Cell 1998; 92: 183-192.
298. Colanzi A, Deerinck TJ, Ellisman MH, et al. A specific activation of the mitogen-activated protein kinase kinase 1 (MEK1) is required for Golgi fragmentation during mitosis, J Cell Biol 2000; 149: 331-339.
299. Lowe M, Rabouille C, Nakamura N, et al. Cdc2 kinase directly phosphorylates the cis-Golgi matrix protein GM130 and is required for Golgi fragmentation in mitosis. Cell 1998; 94: 783-793.
300. Kano F, Takenaka K, Yamamoto A, et al. MEK and Cdc2 kinase are sequentially required for Golgi disassembly in MDCK cells by the mitotic Xenopus extracts. J Cell Biol 2000; 149: 357-368.
301. Cha H and Shapiro P. Tyrosine-phosphorylated extracellular signal-regulated kinase associates with the Golgi complex during G2/M phase of the cell cycle. Evidence for regulation of golgi structure. J Cell Biol 2001; 153: 1355-1368.
302. McNally FJ. Modulation of microtubule dynamics during the cell cycle. Curr Opin Cell Biol 1996; 8: 23-29.
303. Preuss U, Doring F, Illenberger S, et al. Cell cycle-dependent phosphorylation and microtubule binding of tau protein stably transfected into Chinese hamster ovary cells. Mol Biol Cell 1995; 6: 1397-1410.
304. Preuss U, Mandelkow EM. Mitotic phosphorylation of tau protein in neuronal cell lines resembles phosphorylation in Alzheimer's disease. Eur J Cell Biol 1998; 76: 176-184
305. Illenberger S, Zheng-Fischhofer Q, Preuss U, et al. The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. Mol Biol Cell 1998; 9: 1495-1512.
306. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 1996; 84: 623-631.
307. Gavet O, Ozon S, Manceau V, et al. The stathmin phosphoprotein family: intracellular localization and effects on the microtubule network. J Cell Sci 1998; 111: 3333-3346.
308. Andersen SS, Ashford AJ, Tournebize R, et al. Mitotic chromatin regulates phosphorylation of Stathmin/Op18. Nature 1997; 389: 640-4543.
309. Kuntziger T, Gavet O, Manceau V, et al. Stathmin/Op18 phosphorylation is regulated by microtubule assembly. Mol Biol Cell 2001; 12: 437-448.
310. Iancu C, Mistry SJ, Arkin S, et al. Effects of stathmin inhibition on the mitotic spindle. J Cell Sci 2001; 114: 909-916.
311. Leighton IA, Curmi P, Campbell DG, et al. The phosphorylation of stathmin by MAP kinase. Mol Cell Biochem 1993; 127-128: 151-156.
312. Moreno FJ, Avila J. Phosphorylation of stathmin modulates its function as a microtubule depolymerizing factor. Mol Cell Biochem 1998; 183: 201-209.
313. Zhong SP, Ma WY, Dong Z. ERKs and p38 Kinases Mediate UVB-induced Phosphorylation of Histone H3 at Serine 10. J Biol Chem 2000.
314. Wei Y, Mizzen CA, Cook RG, et al. Phosphorylation of histone H3 at serine 10 is correlated with chromosome condensation during mitosis and meiosis in Tetrahymena. Proc Natl Acad Sci USA 1998; 95: 7480-7484.
315. Wei Y, Yu L, Bowen J, et al. Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. Cell 1999; 97: 99-109.
316. Sif S, Stukenberg PT, Kirschner MW, et al. Mitotic inactivation of a human SWI/SNF chromatin remodeling complex. Genes Dev 1998; 12: 2842-2851.
317. Takenaka K, Moriguchi T, Nishida E. Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest. Science 1998; 280: 599-602.
318. Kurata S. Selective activation of p38 MAPK cascade and mitotic arrest caused by low level oxidative stress. J Biol Chem 2000; 275: 23413-23416.
319. Bulavin DV, Higashimoto Y, Popoff IJ, et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 2001; 411: 102-107.
320. Maundrell K, Antonsson B, Magnenat E, et al. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress- activated protein kinases in the presence of the constitutively active GTP-binding protein Racl. J Biol Chem 1997; 272: 25238-25242.
321. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19: 8469-8478.
322. Ling YH, Tornos C, Perez-Soler R. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem 1998; 273: 18984-18991
323. Yujiri T, Fanger GR, Garrington TP, et al. MEK kinase 1 (MEKK1) transduces c-Jun NH2-terminal kinase activation in response to changes in the microtubule cytoskeleton. J Biol Chem 1999; 274: 12605-12610.
324. Ponder BA. Cancer genetics. Nature 2001; 411: 336-341.
325. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96: 4240-4245.
326. Tolkacheva T, Chan AM. Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene. Oncogene 2000; 19: 680-689.
327. Bardwell L, Cook JG, Voora D, et al. Repression of yeast Ste12 transcription factor by direct binding of unphosphorylated Kss1 MAPK and its regulation by the Ste7 MEK. Genes Dev 1998; 12: 2887-2898.
328. Shapiro PS, Whalen AM, Tolwinski NS, et al. Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol Cell Biol 1999; 19: 3551-3560.
329. Yu Y, Sato JD. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 1999; 178: 235-246.
330. Baek JH, Jang JE, Kang CM, et al. Hypoxia-induced VEGF enhances tumor survivability via suppression of selum deprivation-induced apoptosis. Oncogene 2000; 19: 4621-4631.
331. Damert A, Ikeda E, Risau W. Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular- endothelial growth factor expression in C6 glioma cells. Biochem J 1997; 327: 419-423.
332. Jung YD, Nakano K, Liu W, et al. Extracellular signal-regulated kinase activation is required for up- regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. Cancer Res 1999; 59: 4804-4807.
333. Berra E, Milanini J, Richard DE, et al. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 2000; 60: 1171-1178.
334. Mendel DB, Schreck RE, West DC, et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 2000; 4848-4858.
335. Carter SK. Clinical strategy for the development of angiogenesis inhibitors. Oncologist 2000; 51-54.
336. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectium antitumor efficacy. Cancer Res 2000; 60: 970-975.
337. Wedge SR and Ogilvie DJ. Inhibition of VEGF signal transduction. Identification of ZD4190. Adv Exp Med Biol 2000; 476: 307-310.
338. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 127-137.
339. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overcxpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825-2831.
340. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cartcer trials. Semin Oncol 2001; 28: 13-19.
341. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19: 6550-6565.
342. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904-914.
343. Graus-Porta D, Beerli RR, Hynes NE. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 1995; 15: 1182-1191.
344. Suzuki T, Ohkawa T, et al. Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells. Gene Ther 2000; 241-248.
345. Weng DE, Usman N. Angiozyme: a novel angiogenesis inhibitor. Curr Oncol Rep 2001; 141-146.
346. Panchal RG. Novel therapeutic strategies to selectively kill cancer cells. Biochem Pharmacol 1998; 55: 247-252.
347. van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197-3204.
348. Schlaepfer DD, Hunter T. Focal adhesion kinase overexpression enhances ras-dependent integrin signaling to ERK2/mitogen-activated protein kinase through interactions with and activation of c-Src. J Biol Chem 1997; 272: 13189-13195.
349. Zohn IM, Campbell SL, Khosravi-Far R, et al. Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene 1998; 17: 1415-1438.
350. Clarke D J, Gimenez-Abian JF. Checkpoints controlling mitosis. Bioessays 2000; 22: 351-363.
351. Taylor SJ, Shalloway D. Src and the control of cell division. Bioessays 1996; 18: 9-11
352. Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 1459-1465.
353. Baselga J. Clinical trials of Herceptin(trastuzumab). Eur J Cancer 2001; 37 Suppl S18-24.